comparemela.com

Latest Breaking News On - Esophageal adenocarcinoma - Page 4 : comparemela.com

Zolbetuximab improves survival in patients with advanced or metastatic gastric adenocarcinoma

1. Median progression-free survival in zolbetuximab group was greater than in the placebo group (10.6 months vs. 8.7 months). 2. There were significantly more serious adverse events in the Zolbetuximab group with nausea, vomiting, and decreased appetite being the most common symptoms. Evidence Rating Level: 1 (Excellent) Study Rundown: First-line treatment for gastric and gastro-esophageal

Esophageal Cancer May Be Treated and Detected by New RNA Molecules

Esophageal Cancer May Be Treated and Detected by New RNA Molecules
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

Gilead and Kite Oncology to Showcase Advances Across the Pipeline Aiming to Address Unmet Needs in Cancer Care at ASCO 2023

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.